Navigation Links
K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice
Date:12/7/2011

ntitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float;

(11) the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, its other indebtedness;  and

(12) the risks detailed from time to time in the Company's filings with the SEC. This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

Because the factors referred to above, as well as the statements included in Part I, Item 1A—"Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended March 31, 2011, and Part II, Item 1A—"Risk Factors," and Part I, Item 2—"Management's Discussion and Analysis of Financial Condition and Results of Operations"  of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to us are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included under Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2011, and Part II, Item 1A under our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011, as supplemented by our subsequent SEC filings. Further, any forward-looking statement speaks only as of the date on which it is made and we are under no obligation to update any of the forward-looking statements after the date of this release. New factors emerge from time to time, and it is not possible for us to predict which factors will arise, when they will arise and/or t
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
2. Onyx Pharmaceuticals to Host a Teleconference to Reprise Key Data From the American Society of Hematology Meeting
3. Bayer HealthCare LLC Stops Trademark Infringement by Indian Pharmaceutical Company
4. Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical Indias Largest Pharmaceutical Companies for $105,000
5. Global Pharmaceutical Services Company Turns to Glowpoints OpenVideo™ Cloud
6. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
7. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
8. UHC Launches RxLINK™, Gives Hospitals Unprecedented Insight Into Pharmaceutical Pricing
9. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
10. Par Pharmaceutical to Host Analyst Day on January 6, 2012
11. Radient Pharmaceuticals Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  In today,s ever-changing marketplace, call centers ... mobile, increasingly connected, and increasingly impatient with slow service. ... interaction channels and tools is driving call centers to ... According to research by benchmarking firm, Best ... segment in a call center study realize the impact ...
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... RnRMarketResearch.com adds Syringes and ... that provides an overview of syringes and needles ... in-house databases, secondary and primary research. ... pipeline spread across 124 pages, talking about 13 ... 5 figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... July 28, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... developer, manufacturer and marketer of orthopedic implants in China, today ... financial results on August 16, 2011, before the market opens. ... a.m. ET on August 16, 2011 to discuss second quarter ...
... Soligenix, Inc. (Soligenix or the Company) (OTC BB: ... amendment of its North American licensing partnership with Sigma ... development and commercialization of orBec® (oral beclomethasone dipropionate or ... part of the amended agreement, Sigma - Tau has ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 2Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 3Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 4Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 5Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 6Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 7Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 8
(Date:8/3/2015)... ... 2015 , ... Bayer has agreed to pay $56.9 million to set up ... alleged to have suffered an arterial blood clot including stroke and heart attack. The ... Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s ... offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and ... Annually, more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive and ... from healthcare organizations with access to the tactics, techniques and practices required to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... is predicted to decline by 39 percent, according to market research compiled for ... includes data from the U.S. Department of Labor, Bureau of Labor Statistics. As ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... A novel research finding from the investigators of Ohio ... of combination of metals like copper with organic chemicals ... range of diseases that are caused by virus.// ... of HIV and Hepatitis C virus RNA in the ...
... of middle-aged women and is characterized by recurring discomfort ... Symptoms vary and can include a combination of mild ... and pelvic area; and an urgent and/or frequent need ... become scarred or irritated, and pinpoint bleeding may appear ...
... HIV infection among its cadres, the Border Security Force ... outpost along West Bengal's international boundary. // ... launched in collaboration with the state AIDS control society ... troopers. ,"We are setting up these condom counters ...
... household activities like cleaning the house and the backyards, ... of prehypertension in people. // ,The study ... daily lifestyle physical activity had the effect of dropping ... hypertensive to prehypertensive and from prehypertensive to normal -- ...
... discriminate between self and non-self. If not for the ... would have lost its power to fight against diseases ... system produces certain substances called antibodies, which identify the ... "bad" so that other divisions of the immune system ...
... strong and science weak, men mistook magic for medicine; now, ... for magic. ~Thomas Szasz, The Second Sin, 1973 ... regarded as a forbidden organ too delicate to tamper with. ... World War II. Military doctors, facing injury and suffering on ...
Cached Medicine News:Health News:Metal In Medicines Can Fight Diseases Effectively 2Health News:Marijuana-Derived Drug Promises Hope In Treating Bladder Infection 2Health News:Free Condom Counters For Border Security Force Cadres 2Health News:Fighting against disease as easy as eating eggs 2Health News:Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well 2
... System includes: Mx3005P instrument and custom ... five (5) filters. The standard filter ... HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 ... includes notebook computer, Mx3005P analysis software, ...
... temperature cyclers, the gradient block can be set ... to 14 or 22 across the 40- or ... up to 2C between adjacent wells in each ... 12 different annealing temperatures in a single experiment. ...
... The system includes: Mx3005P instrument and ... of five (5) filters. The standard ... (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), ... included: desktop computer, Mx3005P analysis software, ...
... includes: Mx3005P instrument and custom filter ... (5) filters. The standard filter set ... (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) ... computer, Mx3005P analysis software, Beacon Designer ...
Medicine Products: